Journal of Gastrointestinal Cancer

, Volume 50, Issue 4, pp 991–996 | Cite as

Musculoskeletal Metastasis from Primary Rectal Cancer: Series of Two Cases of a Very Rare Occurrence with a Short Literature Review

  • Sankalp SinghEmail author
  • Niharika Bisht
  • Richa Joshi
  • Prabha Shankar Mishra
  • Deepak Mulajker
  • Samir Gupta
Case Report


As per Globacan 2012, colorectal cancer is the fourth most common cancer afflicting the worldwide population. It is estimated that around 50–60% of all colorectal malignancies will develop metastasis [1, 2] with the liver and lung being the most common sites for such metastasis. Less commonly involved sites include the peritoneum, and rarely involvement of bone, brain, and spleen is seen [3]. Metastatic cancer deposits in skeletal muscles are extremely rare from the gastrointestinal tract and despite a rigorous search of published literature, only 16 case reports of skeletal metastasis from colorectal cancers were found with only five of them originating from the rectum [4]. The management is not clearly defined in such a scenario and the prognosis remains guarded.

Case Report

Case 1

A 24-year-old male presented to this hospital with complaints of bleeding per rectum for the past 2 months. He gave history of having undergone a hemorrhoidectomy 3 months previously for...



We would like to acknowledge the Departments of Pathology, Radiology, and Nuclear Medicine at Command Hospital (SC), Pune, for their support.

Compliance with Ethical Standards

Conflict of Interest

The authors declare that they have no conflict of interest.


  1. 1.
    Lee WS, Yun SH, Chun HK, Lee WY, Yun HR, Kim J, et al. Pulmonary resection for metastases from colorectal cancer: prognostic factors and survival. Int J Color Dis. 2007;22:699–704.CrossRefGoogle Scholar
  2. 2.
    Van Cutsem E, Nordlinger B, Adam R, Köhne CH, Pozzo C, Poston G, et al. Towards a pan-European consensus on the treatment of patients with colorectal liver metastases. Eur J Cancer. 2006;42(14):2212–21.CrossRefGoogle Scholar
  3. 3.
    Tunio MA, AlAsiri M, Riaz K, AlShakwer W, AlArifi M. Skeletal muscle metastasis secondary to adenocarcinoma of colon: a case report and review of literature. J Gastroint Dig Syst. 2013;S12:002.CrossRefGoogle Scholar
  4. 4.
    Ünsal D, Üner A, Simsek A, Üzüm N, Akmansu M. Metastatic rectal adenocarcinoma to forearm muscle: an unusual site of metastasis. Turk J Cancer. 2005;35:181–5.Google Scholar
  5. 5.
    Jemal A, Center MM, DeSantis C, Ward EM. Global patterns of cancer incidence and mortality rates and trends. Cancer Epidemiol Biomark Prev. 2010;19:1893–907.CrossRefGoogle Scholar
  6. 6.
    de Gramont A, Bosset JF, Milan C, Rougier P, Bouché O, Etienne PL, et al. Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with bimonthly high-dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer: a French intergroup study. J Clin Oncol. 1997;15:808–15.CrossRefGoogle Scholar
  7. 7.
    Van Cutsem E, Hoff PM, Harper P, Bukowski RM, Cunningham D, Dufour P, et al. Oral capecitabine vs intravenous 5-fluorouracil and leucovorin: integrated efficacy data and novel analyses from two large, randomised, phase III trials. Br J Cancer. 2004;90:1190–7.CrossRefGoogle Scholar
  8. 8.
    Grothey A, Sargent D, Goldberg RM, Schmoll HJ. Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatment. J Clin Oncol. 2004;22:1209–14.CrossRefGoogle Scholar
  9. 9.
    Tournigand C, André T, Achille E, Lledo G, Flesh M, Mery-Mignard D, et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol. 2004;22:229–37.CrossRefGoogle Scholar
  10. 10.
    Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004;350:2335–42.CrossRefGoogle Scholar
  11. 11.
    Van Cutsem E, Köhne CH, Láng I, Folprecht G, Nowacki MP, Cascinu S, et al. Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status. J Clin Oncol. 2011;29:2011–9.CrossRefGoogle Scholar
  12. 12.
    Patel NN, Shah PR, Wilson E, Haray PN. An unexpected supraclavicular swelling. World J Surg Oncol. 2007;5:90.CrossRefGoogle Scholar
  13. 13.
    Hoehn JL, Ousley JL, Avecilla CS. Occult carcinoma of the colon and rectum manifesting as osseous metastasis. Dis Colon Rectum. 1979;22:129–32.CrossRefGoogle Scholar
  14. 14.
    Ihle PM, McBeath AA. Bone metastasis from colonic carcinoma. A case report. J Bone Joint Surg Am. 1973;55:398–400.CrossRefGoogle Scholar
  15. 15.
    Tsai MS, Su YH, Ho MC, Liang JT, Chen TP, Lai HS, et al. Clinicopathological features and prognosis in resectable synchronous and metachronous colorectal liver metastasis. Ann Surg Oncol. 2007;14:786–94.CrossRefGoogle Scholar
  16. 16.
    Hellman S, Weichselbaum RR. Oligometastases. J Clin Oncol. 1995;13:8–10.CrossRefGoogle Scholar
  17. 17.
    Khattak MA, Martin HL, Beeke C, Price T, Carruthers S, Kim S, et al. Survival differences in patients with metastatic colorectal cancer and with single site metastatic disease at initial presentation: results from South Australian clinical registry for advanced colorectal cancer. Clin Colorectal Cancer. 2012;11:247–54.CrossRefGoogle Scholar
  18. 18.
    Nakajima M, Morikawa K, Fabra A, Bucana CD, Fidler IJ. Influence of organ environment on extracellular matrix degradative activity and metastasis of human colon carcinoma cells. J Natl Cancer Inst. 1990;82:1890–8.CrossRefGoogle Scholar
  19. 19.
    Fidler IJ, Wilmanns C, Staroselsky A, Radinsky R, Dong Z, Fan D. Modulation of tumor cell response to chemotherapy by the organ environment. Cancer Metastasis Rev. 1994;13:209–22.CrossRefGoogle Scholar
  20. 20.
    Dalton WS. The tumor microenvironment as a determinant of drug response and resistance. Drug Resist Updat. 1999;2:285–8.CrossRefGoogle Scholar
  21. 21.
    Tarin D. Clinical and biological implications of the tumor microenvironment. Cancer Microenviron. 2012;5:95–112.CrossRefGoogle Scholar
  22. 22.
    Takada J, Watanabe K, Kuraya D, Kina M, Hayashi S, Hamada H, et al. An example of metastasis to the iliopsoas muscle from sigmoid colon cancer. Gan To Kagaku Ryoho. 2011;38(12):2294–7.PubMedGoogle Scholar
  23. 23.
    Naik VR, Jaafar H, Mutum SS. Heterotopic ossification in skeletal muscle metastasis from colonic adenocarcinoma - a case report. Malays J Pathol. 2005;27:119–21.PubMedGoogle Scholar
  24. 24.
    Burgueño Montañés C, López Roger R. Exophthalmos secondary to a lateral rectus muscle metastasis. Arch Soc Esp Oftalmol. 2002;77:507–10.PubMedGoogle Scholar
  25. 25.
    Hasegawa S, Sakurai Y, Imazu H, Matsubara T, Ochiai M, Funabiki T, et al. Metastasis to the forearm skeletal muscle from an adenocarcinoma of the colon: report of a case. Surg Today. 2000;30:1118–23.CrossRefGoogle Scholar
  26. 26.
    Homan HH, Mühlberger T, Kuhnen C, Steinau HU. Intramuscular extremity metastasis of adenocarcinoma of the colon. Chirurg. 2000;71:1392–4.CrossRefGoogle Scholar
  27. 27.
    Bonjer HJ, Lange JF, Jansen A, Schouten WR, Jakimowicz J, Cuesta Valentin MA, et al. Abdominal wall metastasis following surgical removal of colorectal carcinomas. Ned Tijdschr Geneeskd. 1997;141:1868–70.PubMedGoogle Scholar
  28. 28.
    Jacquet P, Averbach AM, Jacquet N. Abdominal wall metastasis and peritoneal carcinomatosis after laparoscopic-assisted colectomy for colon cancer. Eur J Surg Oncol. 1995;21:568–70.CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Malignant Disease Treatment Centre, Command Hospital (SC)PuneIndia

Personalised recommendations